GlassScriptPhysician profile
Candiss Trager
NPI 1881117679
$10,131.82
in general payments reported to CMS, 2019-2025
35 companies · $3,072 in 2025
The $3,072 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,373 · 2022: $1,580 · 2023: $1,633 · 2024: $2,474 · 2025: $3,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,549 · Consulting Fee: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,548.80 |
| Consulting Fee | $630.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,330.55 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,484.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $1,230.61 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $774.01 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $743.82 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $730.19 | 2021-2024 | Yupelri, Yupelri |
| United Therapeutics Corporation | $589.66 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Actelion Pharmaceuticals US, INC. | $265.07 | 2021-2024 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $221.23 | 2021-2025 | Glassia |
| Grifols USA, LLC | $192.70 | 2022-2025 | Prolastin-C Liquid |
| Electromed, INC. | $153.76 | 2021-2025 | Smartvest |
| Harmony Biosciences LLC | $152.76 | 2022 | |
| Insmed, INC. | $145.49 | 2021-2025 | Arikayce |
| Verona Pharma, INC. | $144.84 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $132.91 | 2024 | Inspire |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.69 | 2022-2024 | Tezspire |
| Advanced Respiratory, INC | $84.62 | 2021 | |
| Mallinckrodt Hospital Products INC. | $84.11 | 2022-2024 | Acthar |
| Abbvie INC. | $77.36 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $60.58 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.50 | 2023-2024 | |
| Baxter Healthcare | $50.23 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $46.68 | 2024-2025 | Winrevair |
| Philips North America LLC | $44.91 | 2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Viatris Specialty LLC | $39.36 | 2025 | Yupelri |
| Itamar Medical INC | $33.11 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.99 | 2021 | |
| Optinose US, INC. | $23.13 | 2024 | |
| Pulmonx Corporation | $19.92 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Paratek Pharmaceuticals, INC. | $19.81 | 2021 | |
| Resmed Corp | $17.82 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.96 | 2025 | Alvesco |
| Axsome Therapeutics, INC. | $14.22 | 2024 | Sunosi |
| Ani Pharmaceuticals, INC. | $13.40 | 2024 | Purified Cortrophin Gel |
| Covis Pharma Gmbh | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candiss Trager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.